

### **Abstract**

 The COVID-19 pandemic had a severe impact globally, yet African populations exhibited unexpectedly lower rates of severe disease and mortality. We investigated the potential role of pre-existing immunity in shaping the epidemiology of COVID-19 in Africa. Leveraging paired plasma and peripheral blood mononuclear cells collected from Senegalese female sex workers prior to the COVID-19 pandemic, we observed substantial levels of pre-existing cross-reactive immunity to SARS-CoV-2, stemming from prior exposure to seasonal human coronaviruses (hCoVs). Our antibody analysis revealed a 23.5% (47/200) seroprevalence rate against SARS-CoV-2 nucleocapsid (N). Of these SARS-CoV-2 N-reactives, 85.1% (40/47), 44.7% (21/47), and 95.7% (45/47) showed antibody reactivity against hCoV-229E or hCoV-OC43 spike (S) and/or N or hCoV-HKU1 S. Our analysis of cellular responses also demonstrated cross-reactivity to SARS-CoV-2 with 82.2% (37/45) and 84.4% (38/45) showing IFN-γ responses against S and N, respectively. These findings suggest that prior hCoV exposure may induce cross-reactive adaptive immunity, potentially contributing to protection against COVID- 19. A unique pre-pandemic subject had cross-reactive SARS-CoV-2 S antibodies with detectable neutralization and cellular responses. Our study provides unique insights into the dynamics of hCoV and SARS-CoV-2 immunity in West African populations and underscores the importance of understanding the role of pre-existing immunity in shaping COVID-19 outcomes globally.

#### **Introduction**

 The first COVID-19 cases were recorded on the African continent in March 2020, yet by the end of the pandemic in May 2023, Africa's reported SARS-CoV-2 infections and deaths constituted only 2-4% of the global disease burden despite being home to ~17% of the world's population. Early projections of the COVID-19 pandemic's impact on Africa predicted massive loss of life. Most African countries lacked adequate healthcare infrastructure, workforce, and equipped facilities to cope with a novel and highly infectious respiratory pathogen. However, other characteristics of most African 54 countries suggested different outcomes from what was seen in resource-rich settings.<sup>1</sup> Africa's relatively young population age distribution with lower rates of co-existing morbidities, environmental factors, and pre-existing immunity from exposure to related viruses may explain the unexpected low rates of severe disease and mortality observed 58 in Africa.<sup>2</sup>

 In 2020, SARS-CoV-2 emerged as a new human coronavirus, even though worldwide populations were known to be regularly exposed to seasonal human coronaviruses (hCoVs) responsible for the "common cold," including α-coronaviruses (hCoV-229E, hCoV-NL63,) and β-coronaviruses (hCoV-OC43, hCoV-HKU1). Although associated with mild illness, these hCoVs share genetic similarity to the SARS coronaviruses, which include SARS-CoV-1, SARS-CoV-2, and Middle East Respiratory Syndrome (MERS). hCoVs are globally endemic and estimated to be responsible for up to 15-30% of pre-pandemic annual respiratory infections, which are seasonal (e.g., fall and winter) and most prevalent in young children.

 The widespread circulation of hCoVs with repeated exposure of human populations and shared sequence homology to SARS-CoV-2 led to the suggestion that hCoV immunologic memory could result in cross-reactive cellular and humoral responses that might in part explain the heterogeneity of COVID-19 presenting symptoms and pathogenic outcomes. While not providing sterilizing immunity, pre- existing hCoV immunity could reduce transmission and ameliorate symptoms of the related SARS-CoV-2. Therefore, research has been conducted to determine the role of pre-existing cross-reactive immunity to SARS-CoV-2. Multiple US and European studies described CD4+ T cell reactivity in SARS-CoV-2 unexposed individuals, attributed to pre-existing memory responses to hCoVs. $3-7$  In a UK household study, exposed contacts that remained PCR-negative showed significantly higher frequency of cross- reactive (p=.0139) and nucleocapsid (N)-specific IL-2 secreting memory T cells  $(p=.0355).$ <sup>3</sup> Swadling et al. in a study of potentially abortive SARS-CoV-2 infection in UK healthcare workers (HCWs) described pre-existing T cell reactivity directed against the 82 early transcribed replication-transcription complex (RTC).<sup>4</sup> The RTC, consisting of RNA polymerase co-factor non-structural protein 7 (NSP7), RNA polymerase NSP12 and helicase NSP13, is expressed early in the viral life cycle and is highly conserved among members of *Coronaviridae*. <sup>4</sup> Studies of pre-pandemic samples collected from Africa have also demonstrated cross-reactive T cell responses against several SARS-CoV-2 87 antigens.<sup>5,6</sup> These studies have led to the hypothesis that prior hCoV infection might provide protective cross-reactive memory, perhaps more likely in younger individuals in whom infections with hCoVs are more prevalent and recent. As described by Lipsitch et al., pre-existing cross-reactive memory T cells could lower respiratory tract viral load

 thereby limiting the duration and severity of disease with potential to reduce viral 92 spread.<sup>7</sup>

 Pre-existing antibody studies have also described distinct humoral responses to SARS-CoV-2 associated with prior hCoV infection. Ng et al. described uninfected donors with IgG reactivity to conserved epitopes in the S2 subunit of the SARS-CoV-2 spike (S) protein distinct from de novo humoral responses in infected individuals that 97 targeted both S1 and S2 subunits with concomitant IgM and IgA responses.<sup>8</sup> Multiple studies conducted in the US and Europe have identified antibodies to hCoVs (OC43) 99 that were associated with lower risk of severe COVID-19.<sup>9, 10</sup>

 Over the course of the COVID-19 pandemic in Africa, studies based on SARS- CoV-2 antibody detection described high prevalence rates of infection, in contrast with 102 surveillance data.<sup>11</sup> Yet, even with anticipated underreporting, severe COVID-19 cases 103 and mortality remained unexpectedly low.<sup>12</sup> While multiple factors are likely to contribute to the capacity of individuals to generate cross-reactivity, it is possible that the order and composition of different infections may play a role in determining the efficacy of the immune response in preventing symptomatic or severe COVID-19. Currently, high rates of SARS-CoV-2 infection and COVID-19 vaccine exposure globally challenge the ability to investigate cross-reactive responses in individuals who have not been exposed to SARS-CoV-2. While our research group has reported on SARS-CoV-2 immune 110 responses in Nigeria,<sup>5</sup> in this study we leveraged paired plasma and peripheral blood monocular cell (PBMC) samples collected in Senegal, West Africa prior to the COVID-112 19 pandemic. Our objectives were to measure hCoV seroprevalence rates and to characterize the pre-existing cross-reactive antibody and cellular responses to SARS-

 CoV-2 in our pre-pandemic West African samples. The aim was to understand whether and how pre-existing hCoV immunity might confer protection against severe COVID-19 disease in Africa.

**Methods** 

Human samples:

 The plasma and PBMC archive was developed from our multi-decade prospective cohort study of HIV-1 and HIV-2 in Senegalese female sex workers 123 (FSWs), followed from 1986-2010.<sup>13-15</sup> Self-identified FSW routinely visiting a health care clinic in Dakar provided blood samples to test for multiple sexually transmitted infections, including HIV-1 and HIV-2 and were examined clinically; excess blood samples were de-identified and archived with their corresponding clinical data. More than 80% of women sampled were HIV negative and most had paired plasma and liquid nitrogen preserved PBMCs with accompanying clinical and immunologic data at more than 2 timepoints. The viability and functional integrity of these cryopreserved PBMCs have been previously demonstrated in our studies of HIV and flavivirus T-cell 131 immunity.<sup>16-18</sup> The plasma and PBMC samples tested for this study were collected from 2004 to 2005. At the time of the original study, all women provided informed consent for the collection and archiving of samples and corresponding data; ethical clearance from the Harvard Institutional Review Board (IRB) and the research ethics committee at Chiekh Anta Diop University, Dakar, Senegal were obtained. All archived samples and corresponding data were anonymized, and as such this secondary analysis did not

 constitute human subject research by institutional guidelines and regulations which follow the Federal Policy for Protection of Human Subjects.

Virion-based immunoblots:

 We screened plasma samples by immunoblot assay on virion preparations from SARS-CoV-2. Briefly, Vero E6 cells or susceptible cell line were infected with SARS- CoV-2 (Isolate USA-WA1/2020, BEI Resources NR-52281) or hCoVs (OC43, NL63, 229E, BEI Resources NR-5621, 470 and 52726, respectively) and propagated for five days. Supernatants were clarified at 10,000g for 20min at 4°C, precipitated with PEG- 8000 and NaCl, and then resolved by sucrose gradient ultracentrifugation at 170,000g 146 for 90min at 4°C. Viral pellets were lysed with complete NP40 buffer containing protease inhibitors. Viral lysates were added to nonreducing buffer (final concentrations of 2% SDS, 0·5 M Tris pH 6·8, 20% glycerol, 0·001% bromophenol blue) and subjected to 12% PAGE and Western blot analysis using patient serum (1:250) as primary antibody and anti-human IgG horseradish peroxidase (HRP) (1:2,000; ThermoFisher Scientific, Waltham, MA) as secondary antibody. Visualization was performed using Metal Enhanced DAB Substrate Kit (ThermoFisher Scientific, Waltham, MA) per the manufacturer's instructions.

154 RecomLine SARS-CoV-2 IgG (Mikrogen)<sup>19, 20</sup> is a CE-marked immunoblot assay which determines the IgG responses towards the recombinant N antigens of the seasonal hCoV 229E, OC43, NL63 and HKU-1 in parallel to SARS-CoV-2 N, receptor-binding domain (RBD), and S1 antigens.

## ELISPOT assay:



## **Virus neutralization titer analyses**

 Pseudotype virus neutralization assay was performed on Hela-ACE2 cells using SARS-178 CoV-2 spike pseudotype virus (PV) expressing luciferase as previously described.<sup>23, 24</sup> 179 Briefly, dried plasma spots were eluted and heat inactivated at  $54^{\circ}$ C for 1 hour,<sup>25</sup> and incubated with PVs at 37°C for 1 hour prior to addition of Hela-ACE2 cells. The plasma 181 dilution/virus mix was incubated for 48 hours in a 5%  $CO<sub>2</sub>$  environment at 37 $\degree$ C, and

 luminescence was measured using the Bright-Glo Luciferase assay system (Promega UK, United Kingdom). Neutralization was calculated relative to the virus and cell only 184 controls. Data was analyzed in GraphPad Prism v9.3.1 where 50% neutralization (ID<sub>50</sub>) 185 values were calculated and the limit of detection for neutralization was set at ID<sub>50</sub> of 20 units.

#### **Statistics**





- seroprevalence rates, the 47 samples reactive to SARS-CoV-2 N-only were analyzed
- for antibodies directed against hCoV-229E S and N, hCoV-OC43 S and N, and hCoV-
- HKU1 S. Of the samples tested, 37 (78.7%) samples showed reactivity to hCoV-229E
- S+N, 7 (14.9%) to hCoV-OC43 S+N, and 45 (95.7%) to hCoV-HKU1 S (Fig. 1, Fig. 2B-
- D). Of the 37 hCoV-229E S+N samples, 30 (81.1%) were reactive to S+N, while 7
- (18.9%) were reactive to S-only. Of the 7 hCoV-OC43 S+N samples, 6 (85.7%) were
- reactive to S+N, while 1 (14.3%) was reactive to S-only. Of note, 36 out of the 47
- samples (76.6%) were reactive to both hCoV-229E S and hCoV-HKU1 S
- (Supplementary Fig. 1). Only 6 (12.8%) were reactive to S of hCoV-229E, hCoV-OC43,
- and hCoV-HKU1 (Supplementary Figs. 2-3).
- 

#### *Risk factor analysis*

 Bivariate analysis of risk factors associated with SARS-CoV-2 N antibody reactivity included: year of sampling, age at sampling, neighborhood, ethnicity, country of origin, marital status, religion, education, and total children. There was a potential association between SARS-CoV-2 N-reactive and age >44 years (p=0.078) and with having ≥3 children (p=0.044) (Table 1). Older age had a strong positive correlation with having more children.

*Pre-pandemic cross-reactive T-cell responses to SARS-CoV-2*



 demonstrated strong antibody reactivity to both SARS-CoV-2 S and N (Fig. 1A). Longitudinal antibody analysis of 6 samples collected from this individual between 1997 to 2004 was conducted by SARS-CoV-2 immunoblot as well as the Mikrogen assay that detected antibodies against the individual antigens of SARS-CoV-2 (S, RBD, and N) and hCoVs (HKU1, OC43, NL63, and 229E N). Samples collected in 1997 and 2001 showed antibody reactivity to SARS-CoV-2 N-only by immunoblot with weak antibodies against hCoVs, particularly in the 1997 sample (Fig. 4A-B). Seroconversion to SARS-CoV-2 S (2003) and S and RBD (May to November 2004) was observed by both immunoblot and the Mikrogen assay, accompanied with stronger reactivity to hCoV-HKU1 N and hCoV-OC43 N. This seroprofile is unique from our other pre-pandemic serology and may

 indicate exposure to a novel variant – one more closely related to SARS-CoV-2. Additionally, longitudinal cellular responses were analyzed between 1997 and 2004. In 1997, this individual only had cellular responses against SARS-CoV-2 N. By 2001, this individual had cellular responses against both SARS-CoV-2 S and N that persisted throughout 2004 (Fig. 4C). Sequential analysis of SARS-CoV-2 neutralization revealed no detectable neutralization response against SARS-COV-2 wild-type (Wu-1 614G) in samples collected in 1997 and 2001 but showed detectable neutralization response in 256 samples collected in October 2003 (ID<sub>50</sub> titer=281.3) with waning responses observed in May 2004 (ID<sup>50</sup> titer=195.6); August 2004 (ID<sup>50</sup> titer=121.1) and November 2004 (ID<sup>50</sup> titer=43.3). The observation of detectable responses coincided with seroconversion of S and RBD antibodies reflecting exposure to hCoVs with possible cross-reactive potential due to sequence homogeneity to a SARS-CoV-2 variant. Clinical examination data collected as part of the prospective HIV clinical protocol did not indicate reporting of symptoms or signs of respiratory disease, but the patient was noted to have lost significant (>10%) weight between 2001 to 2003, during which S antibody seroconversion occurred. The patient was also HIV-positive, 43 years of age in 2003, and had 3 living children.

#### **Discussion**

 In early 2021, we studied the immune responses in Nigerian healthcare workers (HCWs) at Lagos University Teaching Hospital (n=134) and in Oxford/AstraZeneca COVID-19 vaccine recipients from the general population (n=116) across five local

272 government areas (LGAs) in Lagos state.<sup>5</sup> Antibodies directed to only SARS-CoV-2 N in the absence of S antibody reactivity were detected in 9.7% (13/134) of HCWs and 15.5% (18/116) of the general population. This antibody profile directed to the SARS- CoV-2 N alone was suggestive of pre-existing cross-reactive immunity stemming from prior hCoV infection. To investigate this possibility further, in this study we tested archived plasma samples collected before the COVID-19 pandemic from our FSW cohort in Dakar, Senegal (2004-2005), and observed 23.5% (47/200) of individuals with pre-existing immunity to SARS-CoV-2 N-only (Fig. 1). Further testing demonstrated prior infections with the seasonal hCoVs, providing evidence that the SARS-CoV-2 N-281 only reactivity resulted from cross-reactivity from prior hCoV exposure (Fig. 1-2). The coronavirus N protein is more conserved than the S protein. As such, previously hCoV exposed individuals can demonstrate cross-reactive N antibodies without cross-reactive 284 S antibodies (Figs.  $1-2$ ).<sup>5, 26</sup>

 In one of the few studies conducted on samples from Africa prior to the COVID- 19 pandemic, Tso et al. reported higher reactivity to hCoV N and S antigens with significantly higher rates of cross-reactivity in Zambia (14.1%) and Tanzania (19%) 288 compared to the US  $(2.4\%)$ .<sup>27</sup> In a multi-national study, Pedersen et al. reported higher SARS-CoV-2 N reactivity in Gabon (20/116,17.2%) compared to reactivity in Canada, Denmark, and Brazil. In samples from Senegal, largely from subjects under 17 years of age, high antibody cross-reactivity to both S and N antigens of SARS-CoV-2 was 292 observed; these samples failed to demonstrate in vitro neutralization.<sup>26</sup> Similar to this Senegal study, our study also detected pre-pandemic antibody cross-reactivity to

 SARS-CoV-2, but we concurrently detected cellular cross-reactivity to support the antibody results.

 While most investigators study T cell responses to specific antigens using overlapping peptides, we have used full-length antigens or large peptides fused to a modified version of the *Bacillus anthracis* lethal factor (LFn). LFn has been shown to act as a molecular shuttle, transporting antigens of interest into the cytosol for MHC Class I and Class II processing for CD4+ and CD8+ T cell presentation. In the past, we have used LFn to study T cell responses against several viruses, including HIV, Ebola, Zika, 302 dengue, and SARS-CoV-2.  $22-24,18$  In our SARS-CoV-2 study of Nigerian HCWs and individuals from the general population, among individuals with SARS-CoV-2 N-only antibodies prior to vaccination, suggestive of prior exposure to hCoV, 81.8% (9/11) had T cell responses to SARS-CoV-2 N. These results provided further evidence that individuals who were previously exposed to hCoVs could have cross-reactive cellular responses against SARS-CoV-2.

 Cross-reactive T cell responses play a protective role in protection against COVID-19. Cellular responses were shown to map to cross-reactive recognition of SARS-CoV-2 by T cells induced by hCoVs.<sup>28-31</sup> SARS-CoV-2-specific T cells were also 311 able to cross-react with SARS-CoV-1 and MERS-CoV.  $32-35$  Recently, Tarke et al., demonstrated that pre-pandemic samples collected from healthy adults in the US with confirmed previous exposure to hCoV-NL63 and -OC43 had significant cross-reactive T cell responses to SARS-CoV-2, particularly to conserved regions of SARS-CoV-2 S, N, 315 nsp3, and nsp12.<sup>36</sup> Similarly, Namuniina et al. showed that in pre-pandemic samples collected in Uganda, a majority of subjects had both CD4+ and/or CD8+ T cell

317 responses against  $SARS-CoV-2$  S and non-S peptide pools.<sup>6</sup> This study however did not determine whether pre-existing immunity based on previous exposure to hCoV was responsible for the cross-reactive cellular responses.

 In the current study using pre-pandemic samples collected from Senegalese FSWs, we show evidence of cellular cross-reactivity to SARS-CoV-2 with 82.2% (37/45) and 84.4% (38/45) of PBMC samples matched to SARS-CoV-2 N antibody reactive plasma samples demonstrating IFN-γ responses against S and N, respectively (Fig. 3). Although these N antibody reactive samples showed no S antibody reactivity, the majority demonstrated cross-reactive cellular responses to both SARS-CoV-2 S and N, suggesting that cellular responses against this less conserved region may be more sustained over time than humoral responses. Among the SARS-CoV-2 negative controls, a majority (18/21, 85.7%) did not have cellular responses. However, three control individuals showed weak cellular responses against SARS-CoV-2 S and N. This again may reflect the more temporal nature of humoral immunity compared with the longevity of cellular immunity. Additionally, the individual that initially tested antibody positive for SARS-CoV-2 S-only also had sustained cross-reactive cellular responses to SARS-CoV-2 S and/or N from 1997 to 2004 (Fig. 4C) with evidence of sustained albeit waning neutralization responses from 2003 and 2004 (Fig. 4D).

335 It is unknown whether these cross-reactive cellular responses from prior hCoV infection were sustained at levels that would impact the pathogenesis of SARS-CoV-2 during the 2020 pandemic. Immunologic memory to antigenically related infections can result in both positive and negative patient outcomes. As described in influenza, the induction of antibody responses to new virus infection can "backboost" responses to

340 preceding heterologous viruses. In contrast, prior heterologous responses with reduced functionality may misdirect new responses resulting in negative clinical 342 outcomes, i.e. "original antigenic sin"<sup>38, 39</sup>, particularly in antigenically shifting viruses such as SARS COV-2. Our results show significant prior hCoV infection with demonstrable antibodies to SARS-CoV-2 N and cellular responses to S and N, which when taken in consideration with low rates of severe COVID-19 disease and mortality in Africa, suggest through indirect association the possibility that prior hCoV infection provides cross-reactive protective immunity in SARS-CoV-2 infection. In our risk factor analysis, we saw potential higher risk of SARS-CoV-2 N reactivity, suggesting previous hCoV infection, in women who were >44 years of age and who had ≥3 children. This might be explained by older women having had more children, and therefore increased exposure to respiratory illnesses from young and school-aged children amongst whom susceptibility to infection and transmission may be highest.

 Our study of pre-pandemic immunologic reactivity to SARS-CoV-2 in Senegal is unique in its assessment of both antibody and cellular responses. However, our study has limitations. We were unable to evaluate the cellular immune responses to hCoVs to verify the proposed source of SARS CoV-2 cross-reactive IFN-γ cellular responses. Our assessment of primary hCoV infection was based on serologic reactivity to hCoV S, which may not be diagnostic of hCoV infection or correlate with hCoV N reactivity or cross-reactivity to SARS-CoV-2 N. We were unable to directly test our hypothesis by demonstrating that a significant fraction of the population possessed antibody and cellular cross-reactive immune responses to SARS-CoV-2 at the time of the pandemic.

 Also, our study analyzed samples from only adult females, who may have different immune responses than males and children.



#### **Role of the funding source**

 Authors declare that the funder did not have any role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

#### **References**

 1. Blanton RE, Mock NB, Hiruy HN, Schieffelin JS, Doumbia S, Happi C, Samuels RJ, Oberhelman RA. African Resources and the Promise of Resilience against COVID- 19. Am J Trop Med Hyg. 2020. Epub 2020/06/06. doi: 10.4269/ajtmh.20-0470. PubMed PMID: 32500851.

 2. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo

 E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2020. Epub 2020/11/13. doi: 10.1126/science.abe1916. PubMed PMID: 33177105. 3. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, Conibear E, Koycheva A, Davies M, Tolosa-Wright M, Hakki S, Varro R, McDermott E, Hammett S, Cutajar J, Thwaites RS, Parker E, Rosadas C, McClure M, Tedder R, Taylor GP, Dunning J, Lalvani A. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022;13(1):80. Epub 20220110. doi: 10.1038/s41467-021-27674-x. PubMed PMID: 35013199; PMCID: PMC8748880.

4. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C,

Gibbons JM, Le Bert N, Tan AT, Jeffery-Smith A, Tan CCS, Tham CYL, Kucykowicz S,

Aidoo-Micah G, Rosenheim J, Davies J, Johnson M, Jensen MP, Joy G, McCoy LE,

Valdes AM, Chain BM, Goldblatt D, Altmann DM, Boyton RJ, Manisty C, Treibel TA,

Moon JC, Investigators CO, van Dorp L, Balloux F, McKnight A, Noursadeghi M,

Bertoletti A, Maini MK. Pre-existing polymerase-specific T cells expand in abortive

seronegative SARS-CoV-2. Nature. 2022;601(7891):110-7. Epub 20211110. doi:

10.1038/s41586-021-04186-8. PubMed PMID: 34758478; PMCID: PMC8732273.

5. Akanmu AS, Herrera BB, Chaplin B, Ogunsola F, Oshibogun A, Onawoga F,

John-Olabode S, Akase IE, Nwosu A, Hamel DJ, Chang CA, Kanki PJ. High SARS-

 CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular responses. J Clin Viro Plus. 2023;3(3):100156. doi: [https://doi.org/10.1016/j.jcvp.](https://doi.org/10.1016/j.jcvp) 2023.100156. 6. Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, Hills N, Nanteza A, Bagaya BS, Weiskopf D, Riou C, Reynolds SJ, Galiwango RM, Redd AD. Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study. PLOS Glob Public Health. 2023;3(8):e0001566. Epub 20230816. doi: 10.1371/journal.pgph.0001566. PubMed PMID: 37585383; PMCID: PMC10431628. 7. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat Rev Immunol. 2020;20(11):709-13. Epub 2020/10/08. doi: 10.1038/s41577-020-00460-4. PubMed PMID: 33024281; PMCID: PMC7537578. 8. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, Shin GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR, Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339-43. Epub 20201106. doi: 10.1126/science.abe1107. PubMed PMID: 33159009; PMCID: PMC7857411. 9. Dugas M, Grote-Westrick T, Merle U, Fontenay M, Kremer AE, Hanses F, Vollenberg R, Lorentzen E, Tiwari-Heckler S, Duchemin J, Ellouze S, Vetter M, Furst J,



- Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies
- patients at risk of critical COVID-19. J Clin Virol. 2021;139:104847. Epub 20210424.
- doi: 10.1016/j.jcv.2021.104847. PubMed PMID: 33965698; PMCID: PMC8065244.
- 10. Dugas M, Grote-Westrick T, Vollenberg R, Lorentzen E, Brix T, Schmidt H,
- Tepasse PR, Kuhn J. Less severe course of COVID-19 is associated with elevated
- levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV
- OC43, HCoV HKU1). Int J Infect Dis. 2021;105:304-6. Epub 20210223. doi:
- 10.1016/j.ijid.2021.02.085. PubMed PMID: 33636357; PMCID: PMC7901274.
- 11. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, Nardone A, Valenciano M,
- Cheng B, Noel K, Cao C, Yanes-Lane M, Herring BL, Talisuna A, Ngoy N, Balde T,
- Clifton D, Van Kerkhove MD, Buckeridge D, Bobrovitz N, Okeibunor J, Arora RK,
- Bergeri I, Group USC. SARS-CoV-2 infection in Africa: a systematic review and meta-
- analysis of standardised seroprevalence studies, from January 2020 to December 2021.
- BMJ Glob Health. 2022;7(8). doi: 10.1136/bmjgh-2022-008793. PubMed PMID:
- 35998978; PMCID: PMC9402450.
- 12. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. Nat Rev
- Immunol. 2021;21(8):469-70. Epub 20210624. doi: 10.1038/s41577-021-00579-y.
- PubMed PMID: 34168345; PMCID: PMC8222946.
- 13. Kanki PJ, Travers KU, S MB, Hsieh CC, Marlink RG, Gueye NA, Siby T, Thior I,
- Hernandez-Avila M, Sankale JL, et al. Slower heterosexual spread of HIV-2 than HIV-1.
- Lancet. 1994;343(8903):943-6. doi: 10.1016/s0140-6736(94)90065-5. PubMed PMID:
- 7909009.

 14. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265(5178):1587-90. doi: 10.1126/science.7915856. PubMed PMID: 7915856. 15. Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup S, Kanki PJ. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses. 2007;23(10):1189-96. doi: 10.1089/aid.2007.0037. PubMed PMID: 17961103. 16. Herrera BB, Tsai WY, Chang CA, Hamel DJ, Wang WK, Lu Y, Mboup S, Kanki PJ. Sustained Specific and Cross-Reactive T Cell Responses to Zika and Dengue Virus NS3 in West Africa. J Virol. 2018;92(7). Epub 2018/01/13. doi: 10.1128/jvi.01992-17. PubMed PMID: 29321308; PMCID: PMC5972862. 17. Sarr AD, Lu Y, Sankale JL, Eisen G, Popper S, Mboup S, Kanki PJ, Cao H. Robust HIV type 2 cellular immune response measured by a modified anthrax toxin- based enzyme-linked immunospot assay. AIDS Res Hum Retroviruses. 2001;17(13):1257-64. doi: 10.1089/088922201750461311. PubMed PMID: 11559425. 18. Hanson A, Sarr AD, Shea A, Jones N, Mboup S, Kanki P, Cao H. Distinct profile of T cell activation in HIV type 2 compared to HIV type 1 infection: differential mechanism for immunoprotection. AIDS Res Hum Retroviruses. 2005;21(9):791-8. doi: 10.1089/aid.2005.21.791. PubMed PMID: 16218803. 19. Bauer G. The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity). J

 Med Virol. 2021;93(1):311-22. Epub 20200715. doi: 10.1002/jmv.26262. PubMed PMID: 32633840; PMCID: PMC7361859.

20. Struck F, Schreiner P, Staschik E, Wochinz-Richter K, Schulz S, Soutschek E,

Motz M, Bauer G. Incomplete IgG avidity maturation after seasonal coronavirus

infections. J Med Virol. 2022;94(1):186-96. Epub 20210827. doi: 10.1002/jmv.27291.

PubMed PMID: 34427932.

21. Herrera BB, Hamel DJ, Oshun P, Akinsola R, Akanmu AS, Chang CA, Eromon

P, Folarin O, Adeyemi KT, Happi CT, Lu Y, Ogunsola F, Kanki PJ. A modified anthrax

toxin-based enzyme-linked immunospot assay reveals robust T cell responses in

symptomatic and asymptomatic Ebola virus exposed individuals. PLoS Negl Trop Dis.

2018;12(5):e0006530. Epub 2018/05/26. doi: 10.1371/journal.pntd.0006530. PubMed

PMID: 29795572; PMCID: PMC5991402.

22. Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, Wang WK, Kanki

PJ. T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and

Zika Viruses. MBio. 2018;9(4). doi: 10.1128/mBio.00755-18. PubMed PMID: 30087165;

PMCID: PMC6083909.

23. Abdullahi A, Oladele D, Owusu M, Kemp SA, Ayorinde J, Salako A, Fink D, Ige

F, Ferreira I, Meng B, Sylverken AA, Onwuamah C, Boadu KO, Osuolale K, Frimpong

JO, Abubakar R, Okuruawe A, Abdullahi HW, Liboro G, Agyemang LD, Ayisi-Boateng

NK, Odubela O, Ohihoin G, Ezechi O, Kamasah JS, Ameyaw E, Arthur J, Kyei DB,

Owusu DO, Usman O, Mogaji S, Dada A, Agyei G, Ebrahimi S, Gutierrez LC, Aliyu SH,

Doffinger R, Audu R, Adegbola R, Mlcochova P, Phillips RO, Solako BL, Gupta RK.

SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nat

Commun. 2022;13(1):6131. Epub 20221017. doi: 10.1038/s41467-022-33792-x.

PubMed PMID: 36253377; PMCID: PMC9574797.

- 24. Abdullahi A, Frimpong J, Cheng MTK, Aliyu SH, Smith C, Abimiku A, Phillips RO,
- Owusu M, Gupta RK. Performance of SARS COV-2 IgG Anti-N as an Independent
- Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population. Am J
- Trop Med Hyg. 2023;109(4):890-4. Epub 20230814. doi: 10.4269/ajtmh.23-0179.
- PubMed PMID: 37580023; PMCID: PMC10551093.
- 25. Wong MP, Meas MA, Adams C, Hernandez S, Green V, Montoya M, Hirsch BM,
- Horton M, Quach HL, Quach DL, Shao X, Fedrigo I, Zermeno A, Huffaker J, Montes R,

Madden A, Cyrus S, McDowell D, Williamson P, Contestable P, Stone M, Coloma J,

Busch MP, Barcellos LF, Harris E. Development and Implementation of Dried Blood

Spot-Based COVID-19 Serological Assays for Epidemiologic Studies. Microbiol Spectr.

2022;10(3):e0247121. Epub 20220525. doi: 10.1128/spectrum.02471-21. PubMed

PMID: 35612315; PMCID: PMC9241704.

26. Pedersen J, Koumakpayi IH, Babuadze G, Baz M, Ndiaye O, Faye O, Diagne

CT, Dia N, Naghibosadat M, McGeer A, Muberaka S, Moukandja IP, Ndidi S, Tauil CB,

Lekana-Douki JB, Loucoubar C, Faye O, Sall A, Magalhaes KG, Weis N, Kozak R,

Kobinger GP, Fausther-Bovendo H. Cross-reactive immunity against SARS-CoV-2 N

protein in Central and West Africa precedes the COVID-19 pandemic. Sci Rep.

2022;12(1):12962. Epub 20220728. doi: 10.1038/s41598-022-17241-9. PubMed PMID:

35902675; PMCID: PMC9333058.

27. Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, Ngalamika

O, Julius P, West JT, Wood C. High prevalence of pre-existing serological cross-

- reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in
- sub-Saharan Africa. Int J Infect Dis. 2021;102:577-83. Epub 20201108. doi:
- 10.1016/j.ijid.2020.10.104. PubMed PMID: 33176202; PMCID: PMC7648883.
- 28. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC,
- Rawlings SA, Smith DM, Phillips E, Mallal S, Lammers M, Rubiro P, Quiambao L,
- Sutherland A, Yu ED, da Silva Antunes R, Greenbaum J, Frazier A, Markmann AJ,
- Premkumar L, de Silva A, Peters B, Crotty S, Sette A, Weiskopf D. Selective and cross-
- reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science.
- 2020;370(6512):89-94. Epub 20200804. doi: 10.1126/science.abd3871. PubMed PMID:
- 32753554; PMCID: PMC7574914.
- 29. Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, Kern F, Schwarz T,
- Mangold M, Unger C, Dorfler F, Kadler S, Rosowski J, Gurcan K, Uyar-Aydin Z,
- Frentsch M, Kurth F, Schnatbaum K, Eckey M, Hippenstiel S, Hocke A, Muller MA,
- Sawitzki B, Miltenyi S, Paul F, Mall MA, Wenschuh H, Voigt S, Drosten C, Lauster R,
- Lachman N, Sander LE, Corman VM, Rohmel J, Meyer-Arndt L, Thiel A, Giesecke-Thiel
- C. Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon
- infection and vaccination. Science. 2021;374(6564):eabh1823. Epub 20211008. doi:
- 10.1126/science.abh1823. PubMed PMID: 34465633; PMCID: PMC10026850.
- 30. Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lubke M,
- Bauer J, Rieth J, Wacker M, Peter A, Horber S, Traenkle B, Kaiser PD, Rothbauer U,
- Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos
- TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jager
- E, Graf M, Gruber LC, Rachfalski D, Preuss B, Hagelstein I, Marklin M, Bakchoul T,



- Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses,
- Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines. J
- Immunol. 2021;206(11):2566-82. Epub 20210428. doi: 10.4049/jimmunol.2001438.
- PubMed PMID: 33911008; PMCID: PMC8722450.
- 35. Rha B, Lively JY, Englund JA, Staat MA, Weinberg GA, Selvarangan R, Halasa
- NB, Williams JV, Boom JA, Sahni LC, Michaels MG, Stewart LS, Harrison CJ, Szilagyi
- PG, McNeal MM, Klein EJ, Strelitz B, Lacombe K, Schlaudecker E, Moffatt ME,
- Schuster JE, Pahud BA, Weddle G, Hickey RW, Avadhanula V, Wikswo ME, Hall AJ,
- Curns AT, Gerber SI, Langley G. Severe Acute Respiratory Syndrome Coronavirus 2
- Infections in Children: Multicenter Surveillance, United States, January-March 2020. J
- Pediatric Infect Dis Soc. 2020;9(5):609-12. doi: 10.1093/jpids/piaa075. PubMed PMID:
- 32556327; PMCID: PMC7337823.
- 36. Tarke A, Zhang Y, Methot N, Narowski TM, Phillips E, Mallal S, Frazier A, Filaci
- G, Weiskopf D, Dan JM, Premkumar L, Scheuermann RH, Sette A, Grifoni A. Targets
- and cross-reactivity of human T cell recognition of Common Cold Coronaviruses.
- bioRxiv. 2023. Epub 20230105. doi: 10.1101/2023.01.04.522794. PubMed PMID:
- 36656777; PMCID: PMC9844015.
- 37. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones
- TC, Le NMH, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le
- TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N,
- de Jong JC, Palache A, Beyer WEP, Le QM, Nguyen TH, Wertheim HFL, Hurt AC,
- Osterhaus A, Barr IG, Fouchier RAM, Horby PW, Smith DJ. Antibody landscapes after

- influenza virus infection or vaccination. Science. 2014;346(6212):996-1000. doi:
- 10.1126/science.1256427. PubMed PMID: 25414313; PMCID: PMC4246172.
- 38. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate
- leukocytes. Nature. 1977;265(5596):739-41. PubMed PMID: 404559.
- 39. Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD,
- Okba NM, Haagmans BL, Langerak T, Endeman H, van den Akker JP, Gommers DA,
- van Gorp EC, GeurtsvanKessel CH, de Vries RD, Fouchier RA, Rockx BH, Koopmans
- MP, van Nierop GP. Seasonal coronavirus-specific B cells with limited SARS-CoV-2
- cross-reactivity dominate the IgG response in severe COVID-19. The Journal of clinical
- investigation. 2021;131(21). doi: 10.1172/JCI150613. PubMed PMID: 34499051;
- PMCID: PMC8553556.



**Fig. 1. SARS-CoV-2 and hCoVs seroprevalence rates. A) Schematic representation of serology workflow.** \*, Samples were analyzed against hCoV-HKU1 S only. B) 200 samples were initially tested against SARS-CoV-2 S and N; 47 samples had antibodies against SARS-CoV-2 N-only (blue donut chart). These 47 samples were then tested against hCoV-229E S and N (green donut chart), hCoV-OC43 S and N (purple donut chart), and hCoV-HKU1 S (yellow donut chart).



**Fig. 2. SARS-CoV-2 and hCoV antibody cross-reactive in samples collected pre-pandemic.** Plasma collected from FSWs prior to the COVID-19 pandemic were subjected to immunoblot analysis. Representative images of immunoblots for samples that had antibodies for A) SARS-CoV-2 N-only or were negative, B) hCoV-229E S+N/S-only, N-only, or were negative, C) hCoV-OC43 S+N, N-only, or were negative, and D) hCoV-HKU1 S or were negative.

		N reactive	N non-reactive		Chi-square* p-	
	No.	%	No.	%	value	
Year of sampling						
2004	74	81.3%	17	18.7%	0.142	
2005	79	72.5%	30	27.5%		
Age at sampling						
≤44 years	92	76.0%	29	24.0%	0.078	
>44 years	22	61.1%	14	38.9%		
Neighborhood						
Dakar	82	75.2%	27	24.8%	0.582	
<b>Outside Dakar</b>	37	71.2%	15	28.8%		
Ethnicity						
Wolof	47	78.3%	13	21.7%	0.188	
Other	68	68.7%	31	31.3%		
Country of origin						
Senegal	106	73.1%	39	26.9%	$0.535*$	
Other	9	64.3%	5	35.7%		
<b>Marital status</b>						
Single	34	77.3%	10	22.7%	$0.578*$	
<b>Divorced</b>	64	71.9%	25	28.1%		
Widowed	$\overline{7}$	63.6%	4	36.4%		
Religion						
<b>Muslim</b>	94	73.4%	34	26.6%	$0.767*$	
Christian	11	68.8%	5	31.3%		
Education						
None	43	69.4%	19	30.6%	0.428	
1-6 years	30	81.1%	$\overline{7}$	18.9%		
7-14 years	30	71.4%	12	28.6%		
<b>Total children</b>						
$0 - 2$	70	78.7%	19	21.3%	0.044	
$\geq 3$	45	64.3%	25	35.7%		

Table 1. Associations between baseline characteristics and SARS-CoV-2 nucleocapsid (N) antibody reactivity (N=2001)

<sup>1</sup> 200 samples tested: 47 SARS-CoV-2 N positive, 153 SARS-CoV-2 N negative. 159 had baseline record.

\*Fisher's exact test was used for variables with cells with observed frequencies ≤5.



Fig. 3. Cross-reactive SARS-CoV-2 cellular responses in samples collected pre-pandemic. PBMCs collected from FSWs prior to the COVID-19 pandemic were stimulated with A) LFn-SARS-CoV-2 S or B) LFn-SARS-CoV-2 N and IFN-γ responses were detected by ELISPOT. SFC, spot forming cells. Black dotted lines, LFn-SARS-CoV-2 S and N cutoffs.

A



**Fig. 4. Evidence for pre-pandemic SARS-CoV-2 variant.** Longitudinally collected plasma samples collected from a FSW between 1997 and 2004 were subjected to A) SARS-CoV-2 immunoblots or the commercial B) Mikrogen assay. C) Paired PBMCs samples were stimulated with LFn-SARS-CoV-2 S or LFn-SARS-CoV-2 N and IFN-γ responses were detected by ELISPOT. SFC, spot forming cells. Light blue dotted line, LFn-SARS-CoV-2 S cutoff. Dark blue dotted line, , LFn-SARS-CoV-2 N cutoff. D) Plasma neutralization (Log10) of pseudotype virus against SARS COV-2 Wild type (Wu-1) in one individual with longitudinal samples collected between 1997 and 2004 including two positive controls from SARS CoV-2 infected and vaccinated adults in 2021 and prepandemic human sera as negative control. Results displayed under the x-axis correspond to their antibody reactivity via immublot assays.





# **Supplementary Fig. 1. Overlap in reactivity between hCoV-229E and hCoV-OC43**.

**Supplementary Fig. 2. Overlap in reactivity between hCoV-229E S and hCoV-HKU1 S.**

				229E		
		S-only	$S+N$	N-only	Negative	<b>TOTAL</b>
HKU-1 S	Spike-reactive		29			45
	Negative					
	<b>TOTAL</b>		30			47

**Supplementary Fig. 3. Overlap in reactivity between hCoV-OC43 S and hCoV-HKU1 S.**

				OC43		
		S-only	$S + N$	N-only	Negative	TOTAL
HKU-1S	Spike-reactive		ь	25	13	45
	Negative					
	<b>TOTAL</b>		o	26	14	47